View Financial HealthBlack Hawk Acquisition 배당 및 자사주 매입배당 기준 점검 0/6Black Hawk Acquisition 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 04/14/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 03Black Hawk Acquisition Corp Receives Non-Compliance Notice from the Nasdaq Stock Market LLCOn March 31, 2026, Black Hawk Acquisition Corporation (the Company) received a notice (the MVLS Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) stating that the Company's market value of listed securities (MVLS) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Market under Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Company has a period of 180 calendar days, or until September 28, 2026 (the MVLS Compliance Date), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the Company's MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company's request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market (the Capital Market), provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. The Notice does not result in the immediate delisting of the Company's class A Ordinary Shares, and the Company's Units, Rights, and Class A Ordinary Shares, will continue to trade uninterrupted on the Nasdaq Global Market under the symbols BKHAU, BKHAR, and BKHA, respectively.공시 • Mar 03Black Hawk Acquisition Corporation announced delayed annual 10-K filingOn 03/02/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Oct 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 10/15/2025, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jun 07Black Hawk Acquisition Corporation Announces Committee and Board ChangesOn April 29, 2025, Black Hawk Acquisition Corporation reported the death of Brandon Miller, a member of the Company’s board of directors and the Chairperson of the Audit Committee. On April 29, 2025, the Board appointed Daniel M. McCabe, a current member of the Board and the then Chairperson of the Compensation Committee, to serve as Chairperson of the Audit Committee. On the same day, Mr. McCabe resigned from his position as Chairperson of the Compensation Committee, and the Board appointed Terry W. Protto, a current member of the Board, to serve as Chairperson of the Compensation Committee.공시 • Apr 29Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million.Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million on April 26, 2025. The Transaction values Vesicor at a pre-money equity value of $70 million. Under the terms of the merge with Vesicor, resulting in Vesicor being the wholly owned subsidiary of Black Hawk, who will continue to be the listed company on the Nasdaq Stock Market and change its name to Vesicor Therapeutics. The Transaction, which has been approved unanimously by the boards of directors of both Black Hawk and Vesicor, is subject to regulatory approvals, the approvals by the shareholders of Black Hawk and Vesicor, respectively, and the satisfaction of certain other customary closing conditions, including, among others, a Form S-4 registration statement under the Securities Act of 1933, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by Nasdaq of the listing application of the combined company. The Business Combination is expected to be completed by the fourth quarter of 2025. Celine & Partners, PLLC acted as legal advisor for Black Hawk Acquisition Corporation. Ogier Global Limited acted as legal advisor for Black Hawk Acquisition Corporation. PW Richter plc acted as legal advisor for Vesicor Therapeutics, Inc.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BKHA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BKHA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Black Hawk Acquisition 배당 수익률 vs 시장BKHA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BKHA)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Capital Markets)2.1%분석가 예측 (BKHA) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BKHA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BKHA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BKHA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BKHA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 03:22종가2026/05/21 00:00수익2026/02/28연간 수익2025/11/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Black Hawk Acquisition Corporation는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 04/14/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 03Black Hawk Acquisition Corp Receives Non-Compliance Notice from the Nasdaq Stock Market LLCOn March 31, 2026, Black Hawk Acquisition Corporation (the Company) received a notice (the MVLS Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) stating that the Company's market value of listed securities (MVLS) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Market under Listing Rule 5450(b)(2)(A) (the MVLS Requirement). The Company has a period of 180 calendar days, or until September 28, 2026 (the MVLS Compliance Date), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the Company's MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company's request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market (the Capital Market), provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. The Notice does not result in the immediate delisting of the Company's class A Ordinary Shares, and the Company's Units, Rights, and Class A Ordinary Shares, will continue to trade uninterrupted on the Nasdaq Global Market under the symbols BKHAU, BKHAR, and BKHA, respectively.
공시 • Mar 03Black Hawk Acquisition Corporation announced delayed annual 10-K filingOn 03/02/2026, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Oct 16Black Hawk Acquisition Corporation announced delayed 10-Q filingOn 10/15/2025, Black Hawk Acquisition Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jun 07Black Hawk Acquisition Corporation Announces Committee and Board ChangesOn April 29, 2025, Black Hawk Acquisition Corporation reported the death of Brandon Miller, a member of the Company’s board of directors and the Chairperson of the Audit Committee. On April 29, 2025, the Board appointed Daniel M. McCabe, a current member of the Board and the then Chairperson of the Compensation Committee, to serve as Chairperson of the Audit Committee. On the same day, Mr. McCabe resigned from his position as Chairperson of the Compensation Committee, and the Board appointed Terry W. Protto, a current member of the Board, to serve as Chairperson of the Compensation Committee.
공시 • Apr 29Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million.Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Black Hawk Acquisition Corporation (NasdaqGM:BKHA) in a reverse merger transaction for $70 million on April 26, 2025. The Transaction values Vesicor at a pre-money equity value of $70 million. Under the terms of the merge with Vesicor, resulting in Vesicor being the wholly owned subsidiary of Black Hawk, who will continue to be the listed company on the Nasdaq Stock Market and change its name to Vesicor Therapeutics. The Transaction, which has been approved unanimously by the boards of directors of both Black Hawk and Vesicor, is subject to regulatory approvals, the approvals by the shareholders of Black Hawk and Vesicor, respectively, and the satisfaction of certain other customary closing conditions, including, among others, a Form S-4 registration statement under the Securities Act of 1933, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by Nasdaq of the listing application of the combined company. The Business Combination is expected to be completed by the fourth quarter of 2025. Celine & Partners, PLLC acted as legal advisor for Black Hawk Acquisition Corporation. Ogier Global Limited acted as legal advisor for Black Hawk Acquisition Corporation. PW Richter plc acted as legal advisor for Vesicor Therapeutics, Inc.